Alessia Stanzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alessia Stanzi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Rolli
Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
3 shared publications - Piergiorgio Solli
Thoracic Surgery Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
3 shared publications - Alessandro Pardolesi
Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
2 shared publications - Clarissa Uslenghi
Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
2 shared publications Federico Mazza
Department of Thoracic Surgery, Santa Croce e Carle General Hospital, Cuneo, Italy
2 shared publications- Giovanni Leuzzi
Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
2 shared publications
Latest Publications
- 2 November 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70792
Perioperative Management of Children, Adolescents and Young Adults Undergoing Surgical Treatment for Oncologic Thoracic Disease: Retrospective Single‐Center Analysis
Background: No guidelines drive the perioperative management of children, adolescents, and young adults (CAYA) undergoing oncologic thoracic surgery. We analyzed our institutional procedures and perioperative results aiming to help develop standardized guidelines. Procedure: Records of CAYA patients operated on for a thoracic tumor (October 2021 to February 2025) were retrospectively analyzed. Standardized perioperative management included minimally invasive technique when feasible, early discharge to the ward, avoidance of sedation (drainage removal), systematic physiotherapy, early mobilization, and resumption of oral intake. Outcomes refer to the total number of surgeries. Results: Forty‐seven CAYA (median age 15, interquartile range [IQR]: 12–18) underwent 54 operations removing localized tumor in 20 (37%), metastases in 33 (61.1%), and one (1.9%) local recurrence. In 36 cases (66.7%), surgery followed chemotherapy after 29.5 days (median; IQR: 22–47.3); in seven (13%), it was performed on a previously irradiated site. Eighteen procedures (33.3%) required resection of more than one organ; 17 (31.5%) were minimally invasive. In 10 (18.5%) cases, the first postoperative night was spent in the intensive care unit. Oral intake was resumed within postoperative day (POD) 1 in 46 (85.2%). Despite physical limitations to ambulation in 12 (22.2%) cases, in 49 (90.7%) the patient was mobilized and in 38 (70.4%) walked within POD1. Continuous intravenous opioid infusion was necessary in 23 (42.6%) cases, and sedation for drainage removal in one. There were 19 complications (35.2%), 89.5% of which were Grade I–II. Patients were discharged on POD5 (median, IQR: 4–8). Conclusions: Standardized perioperative management in CAYA is possible and can lead to early mobilization and a low complication rate, despite complex complementary treatments (chemotherapy/radiotherapy) and limited access to intensive care resources.
- 2 November 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70792
Perioperative Management of Children, Adolescents and Young Adults Undergoing Surgical Treatment for Oncologic Thoracic Disease: Retrospective Single‐Center Analysis
Background: No guidelines drive the perioperative management of children, adolescents, and young adults (CAYA) undergoing oncologic thoracic surgery. We analyzed our institutional procedures and perioperative results aiming to help develop standardized guidelines. Procedure: Records of CAYA patients operated on for a thoracic tumor (October 2021 to February 2025) were retrospectively analyzed. Standardized perioperative management included minimally invasive technique when feasible, early discharge to the ward, avoidance of sedation (drainage removal), systematic physiotherapy, early mobilization, and resumption of oral intake. Outcomes refer to the total number of surgeries. Results: Forty‐seven CAYA (median age 15, interquartile range [IQR]: 12–18) underwent 54 operations removing localized tumor in 20 (37%), metastases in 33 (61.1%), and one (1.9%) local recurrence. In 36 cases (66.7%), surgery followed chemotherapy after 29.5 days (median; IQR: 22–47.3); in seven (13%), it was performed on a previously irradiated site. Eighteen procedures (33.3%) required resection of more than one organ; 17 (31.5%) were minimally invasive. In 10 (18.5%) cases, the first postoperative night was spent in the intensive care unit. Oral intake was resumed within postoperative day (POD) 1 in 46 (85.2%). Despite physical limitations to ambulation in 12 (22.2%) cases, in 49 (90.7%) the patient was mobilized and in 38 (70.4%) walked within POD1. Continuous intravenous opioid infusion was necessary in 23 (42.6%) cases, and sedation for drainage removal in one. There were 19 complications (35.2%), 89.5% of which were Grade I–II. Patients were discharged on POD5 (median, IQR: 4–8). Conclusions: Standardized perioperative management in CAYA is possible and can lead to early mobilization and a low complication rate, despite complex complementary treatments (chemotherapy/radiotherapy) and limited access to intensive care resources.
- Open Access
A Chronobiological Prognostic Model for Resected Stage I Non-Small-Cell Lung Cancer
Objectives: Chronobiology may influence outcomes in non-small-cell lung cancer (NSCLC), but its prognostic role in early-stage disease remains unclear. We evaluated the association between perioperative chronobiological variables, systemic inflammation, and long-term outcomes after complete resection for stage I NSCLC. Methods: 587 patients who underwent curative-intent resection for pathological stage I NSCLC between 2009 and 2018 were retrospectively reviewed. Chronobiological and inflammatory variables included season of surgery (spring/summer [21st March–22nd September], autumn/winter [23rd September–20th March]), time of day, day of week, and preoperative (CRP0 levels: low ≤ 3 mg/L, high > 3 mg/L) and postoperative day-3 (CRP3 levels: low ≤ 126 mg/L, high > 126 mg/L) C-reactive protein levels. The cohort was randomly divided into training (70%) and testing (30%) sets to develop and validate a prognostic model for overall survival (OS), taking into consideration the follow-up time. Disease-free survival (DFS) was analyzed as a secondary endpoint. Results: Median follow-up was 6.7 years, with 80 deaths and 108 recurrences recorded. In the training set, older age (p = 0.0049), stage IB disease (p = 0.0301), high CRP0 (p = 0.0049), and high CRP3 (p = 0.0280) were associated with worse OS, while surgery performed during autumn/winter was associated with improved OS (p = 0.0312). The multivariate Cox model including age, stage, and season of surgery showed the best prognostic performance (C-index 0.67, 95% Bonferroni-adjusted CI 0.50–0.83) and was internally validated in the testing cohort (C-index 0.69, 95%CI 0.52–0.86). The resulting linear predictor remained associated with both OS and DFS in the overall population. Conclusions: A simple model integrating age, pathological stage, and season of surgery was associated with long-term outcomes after surgery in stage I NSCLC. This model provides an exploratory framework integrating host-, tumor-, and chronobiological dimensions of prognosis. These findings require external validation and further investigation of the biological mechanisms underlying seasonal variation.
Open AccessA Chronobiological Prognostic Model for Resected Stage I Non-Small-Cell Lung Cancer
Objectives: Chronobiology may influence outcomes in non-small-cell lung cancer (NSCLC), but its prognostic role in early-stage disease remains unclear. We evaluated the association between perioperative chronobiological variables, systemic inflammation, and long-term outcomes after complete resection for stage I NSCLC. Methods: 587 patients who underwent curative-intent resection for pathological stage I NSCLC between 2009 and 2018 were retrospectively reviewed. Chronobiological and inflammatory variables included season of surgery (spring/summer [21st March–22nd September], autumn/winter [23rd September–20th March]), time of day, day of week, and preoperative (CRP0 levels: low ≤ 3 mg/L, high > 3 mg/L) and postoperative day-3 (CRP3 levels: low ≤ 126 mg/L, high > 126 mg/L) C-reactive protein levels. The cohort was randomly divided into training (70%) and testing (30%) sets to develop and validate a prognostic model for overall survival (OS), taking into consideration the follow-up time. Disease-free survival (DFS) was analyzed as a secondary endpoint. Results: Median follow-up was 6.7 years, with 80 deaths and 108 recurrences recorded. In the training set, older age (p = 0.0049), stage IB disease (p = 0.0301), high CRP0 (p = 0.0049), and high CRP3 (p = 0.0280) were associated with worse OS, while surgery performed during autumn/winter was associated with improved OS (p = 0.0312). The multivariate Cox model including age, stage, and season of surgery showed the best prognostic performance (C-index 0.67, 95% Bonferroni-adjusted CI 0.50–0.83) and was internally validated in the testing cohort (C-index 0.69, 95%CI 0.52–0.86). The resulting linear predictor remained associated with both OS and DFS in the overall population. Conclusions: A simple model integrating age, pathological stage, and season of surgery was associated with long-term outcomes after surgery in stage I NSCLC. This model provides an exploratory framework integrating host-, tumor-, and chronobiological dimensions of prognosis. These findings require external validation and further investigation of the biological mechanisms underlying seasonal variation.
- Open Access
Functional Recovery as a Survivorship Endpoint in Early-Stage NSCLC
Advances in screening, surgical techniques, perioperative care, and multimodality treatment have progressively expanded the population of long-term survivors with early-stage non-small cell lung cancer (NSCLC). However, disease-free survival does not necessarily correspond to complete functional recovery after curative-intent treatment. Many patients continue to experience persistent fatigue, dyspnea, reduced physical activity, impaired exercise tolerance, muscle loss, and deterioration in health-related quality of life despite adequate oncologic control. This narrative review discusses functional recovery as a survivorship endpoint in early-stage NSCLC, focusing on recovery trajectories, physiologic vulnerability, frailty, sarcopenia, rehabilitation, symptom burden, and emerging biologic frameworks such as allostatic load. Increasing evidence suggests that survivorship after NSCLC should not be interpreted exclusively according to recurrence or survival metrics, but also according to the ability to recover physiologic reserve, autonomy, and daily functioning after treatment. Functional recovery appears heterogeneous and influenced by multiple interacting factors, including baseline reserve, systemic inflammation, physical inactivity, behavioral adaptation, and cumulative stress burden. Rehabilitation strategies, structured symptom surveillance, and patient-reported outcomes may help identify vulnerable patients and improve long-term survivorship trajectories. Future survivorship models should probably integrate oncologic outcomes with longitudinal functional assessment to better characterize recovery patterns after treatment.
Open AccessFunctional Recovery as a Survivorship Endpoint in Early-Stage NSCLC
Advances in screening, surgical techniques, perioperative care, and multimodality treatment have progressively expanded the population of long-term survivors with early-stage non-small cell lung cancer (NSCLC). However, disease-free survival does not necessarily correspond to complete functional recovery after curative-intent treatment. Many patients continue to experience persistent fatigue, dyspnea, reduced physical activity, impaired exercise tolerance, muscle loss, and deterioration in health-related quality of life despite adequate oncologic control. This narrative review discusses functional recovery as a survivorship endpoint in early-stage NSCLC, focusing on recovery trajectories, physiologic vulnerability, frailty, sarcopenia, rehabilitation, symptom burden, and emerging biologic frameworks such as allostatic load. Increasing evidence suggests that survivorship after NSCLC should not be interpreted exclusively according to recurrence or survival metrics, but also according to the ability to recover physiologic reserve, autonomy, and daily functioning after treatment. Functional recovery appears heterogeneous and influenced by multiple interacting factors, including baseline reserve, systemic inflammation, physical inactivity, behavioral adaptation, and cumulative stress burden. Rehabilitation strategies, structured symptom surveillance, and patient-reported outcomes may help identify vulnerable patients and improve long-term survivorship trajectories. Future survivorship models should probably integrate oncologic outcomes with longitudinal functional assessment to better characterize recovery patterns after treatment.
- Open Access
Comparison between the Airgo™ Device and a Metabolic Cart during Rest and Exercise
The aim of this study is to compare the accuracy of Airgo™, a non-invasive wearable device that records breath, with respect to a gold standard. In 21 healthy subjects (10 males, 11 females), four parameters were recorded for four min at rest and in different positions simultaneously by Airgo™ and SensorMedics 2900 metabolic cart. Then, a cardio-pulmonary exercise test was performed using the Erg 800S cycle ergometer in order to test Airgo™’s accuracy during physical effort. The results reveal that the relative error median percentage of respiratory rate was of 0% for all positions at rest and for different exercise intensities, with interquartile ranges between 3.5 (standing position) and 22.4 (low-intensity exercise) breaths per minute. During exercise, normalized amplitude and ventilation relative error medians highlighted the presence of an error proportional to the volume to be estimated. For increasing intensity levels of exercise, Airgo™’s estimate tended to underestimate the values of the gold standard instrument. In conclusion, the Airgo™ device provides good accuracy and precision in the estimate of respiratory rate (especially at rest), an acceptable estimate of tidal volume and minute ventilation at rest and an underestimation for increasing volumes.
Open AccessComparison between the Airgo™ Device and a Metabolic Cart during Rest and Exercise
The aim of this study is to compare the accuracy of Airgo™, a non-invasive wearable device that records breath, with respect to a gold standard. In 21 healthy subjects (10 males, 11 females), four parameters were recorded for four min at rest and in different positions simultaneously by Airgo™ and SensorMedics 2900 metabolic cart. Then, a cardio-pulmonary exercise test was performed using the Erg 800S cycle ergometer in order to test Airgo™’s accuracy during physical effort. The results reveal that the relative error median percentage of respiratory rate was of 0% for all positions at rest and for different exercise intensities, with interquartile ranges between 3.5 (standing position) and 22.4 (low-intensity exercise) breaths per minute. During exercise, normalized amplitude and ventilation relative error medians highlighted the presence of an error proportional to the volume to be estimated. For increasing intensity levels of exercise, Airgo™’s estimate tended to underestimate the values of the gold standard instrument. In conclusion, the Airgo™ device provides good accuracy and precision in the estimate of respiratory rate (especially at rest), an acceptable estimate of tidal volume and minute ventilation at rest and an underestimation for increasing volumes.
- 1 June 2020
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 18 (3) , e284-e288
Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma
- 1 June 2020
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 18 (3) , e284-e288
Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma
- 26 October 2017
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 12 (4) , 1661-1667
Tailored intraoperative localization of non‐palpable pulmonary lesions for thoracoscopic wedge resection using hybrid room technology
Introduction: VATS wedge resection can require conversion to thoracotomy when pulmonary lesions cannot be identified. Hybrid operating rooms (HORs) provide real‐time image acquisition capabilities allowing the intraoperative placement of markers to facilitate the removal of non‐palpable nodules during VATS.Objectives: To present our workflow based on the alternative use of two different markers according to the location of the lung lesion and report our initial results.Methods: All consecutive patients with non‐palpable lesions requiring VATS wedge resection underwent localization of the targets in HOR. Lesions were considered non‐palpable if they were small (1 cm from surface), subsolid, or located within a dystrophic area. Anesthetized patients were placed in lateral decubitus. Cone‐beam CT (CBCT) was performed, and the needle trajectory was planned using Syngo iGuide Needle Guidance. Metal hook‐wire or coil was placed, according to our workflow, close to the lesion and their position was verified by CBCT or fluoroscopy.Results: Eleven VATS wedge resections were performed in 10 patients with 12 non‐palpable lesions. The localization was performed with seven hook‐wires and four coils in 30 minutes (range 17‐56 minutes). The median estimated total effective dose was 11.6 mSv (range 1.9‐24.7 mSv). Eleven lesions were removed by VATS, and one deep nodule required a thoracotomy. No complications were observed.Conclusions: Our experience confirms that HOR is suitable for simultaneous localization and VATS resection of ‘difficult’ pulmonary lesions. A versatile approach, using different devices, seems advisable for the removal of targets in every clinical scenario, reducing the VATS conversion rate.
- 26 October 2017
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 12 (4) , 1661-1667
Tailored intraoperative localization of non‐palpable pulmonary lesions for thoracoscopic wedge resection using hybrid room technology
Introduction: VATS wedge resection can require conversion to thoracotomy when pulmonary lesions cannot be identified. Hybrid operating rooms (HORs) provide real‐time image acquisition capabilities allowing the intraoperative placement of markers to facilitate the removal of non‐palpable nodules during VATS.Objectives: To present our workflow based on the alternative use of two different markers according to the location of the lung lesion and report our initial results.Methods: All consecutive patients with non‐palpable lesions requiring VATS wedge resection underwent localization of the targets in HOR. Lesions were considered non‐palpable if they were small (1 cm from surface), subsolid, or located within a dystrophic area. Anesthetized patients were placed in lateral decubitus. Cone‐beam CT (CBCT) was performed, and the needle trajectory was planned using Syngo iGuide Needle Guidance. Metal hook‐wire or coil was placed, according to our workflow, close to the lesion and their position was verified by CBCT or fluoroscopy.Results: Eleven VATS wedge resections were performed in 10 patients with 12 non‐palpable lesions. The localization was performed with seven hook‐wires and four coils in 30 minutes (range 17‐56 minutes). The median estimated total effective dose was 11.6 mSv (range 1.9‐24.7 mSv). Eleven lesions were removed by VATS, and one deep nodule required a thoracotomy. No complications were observed.Conclusions: Our experience confirms that HOR is suitable for simultaneous localization and VATS resection of ‘difficult’ pulmonary lesions. A versatile approach, using different devices, seems advisable for the removal of targets in every clinical scenario, reducing the VATS conversion rate.
- 1 October 2017
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (20) , 417
On the article “prospective study of quality of life after lung cancer resection”
On the article “prospective study of quality of life after lung cancer resection”
- 1 October 2017
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (20) , 417
On the article “prospective study of quality of life after lung cancer resection”
On the article “prospective study of quality of life after lung cancer resection”
- Open Access
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Journal of Transplantation
- Vol. 7 (1) , 70-80
Lobar lung transplantation from deceased donors: A systematic review
To systematically review reports on deceased-donor-lobar lung transplantation (ddLLTx) and uniformly describe size matching using the donor-to-recipient predicted-total lung-capacity (pTLC) ratio. We set out to systematically review reports on ddLLTx and uniformly describe size matching using the donor-to-recipient pTLC ratio and to summarize reported one-year survival data of ddLLTx and conventional-LTx. We searched in PubMed, CINAHL via EBSCO, Cochrane Database of Systematic Reviews via Wiley (CDSR), Database of Abstracts of Reviews of Effects via Wiley (DARE), Cochrane Central Register of Controlled Trials via Wiley (CENTRAL), Scopus (which includes EMBASE abstracts), and Web of Science for original reports on ddLLTx. Nine observational cohort studies reporting on 301 ddLLTx met our inclusion criteria for systematic review of size matching, and eight for describing one-year-survival. The ddLLTx-group was often characterized by high acuity; however there was heterogeneity in transplant indications and pre-operative characteristics between studies. Data to calculate the pTLC ratio was available for 242 ddLLTx (80%). The mean pTLCratio before lobar resection was 1.25 ± 0.3 and the transplanted pTLCratio after lobar resection was 0.76 ± 0.2. One-year survival in the ddLLTx-group ranged from 50%-100%, compared to 72%-88% in the conventional-LTx group. In the largest study ddLLTx (n = 138) was associated with a lower one-year-survival compared to conventional-LTx (n = 539) (65.1% vs 84.1%, P < 0.001). Further investigations of optimal donor-to-recipient size matching parameters for ddLLTx could improve outcomes of this important surgical option.
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Journal of Transplantation
- Vol. 7 (1) , 70-80
Open AccessLobar lung transplantation from deceased donors: A systematic review
To systematically review reports on deceased-donor-lobar lung transplantation (ddLLTx) and uniformly describe size matching using the donor-to-recipient predicted-total lung-capacity (pTLC) ratio. We set out to systematically review reports on ddLLTx and uniformly describe size matching using the donor-to-recipient pTLC ratio and to summarize reported one-year survival data of ddLLTx and conventional-LTx. We searched in PubMed, CINAHL via EBSCO, Cochrane Database of Systematic Reviews via Wiley (CDSR), Database of Abstracts of Reviews of Effects via Wiley (DARE), Cochrane Central Register of Controlled Trials via Wiley (CENTRAL), Scopus (which includes EMBASE abstracts), and Web of Science for original reports on ddLLTx. Nine observational cohort studies reporting on 301 ddLLTx met our inclusion criteria for systematic review of size matching, and eight for describing one-year-survival. The ddLLTx-group was often characterized by high acuity; however there was heterogeneity in transplant indications and pre-operative characteristics between studies. Data to calculate the pTLC ratio was available for 242 ddLLTx (80%). The mean pTLCratio before lobar resection was 1.25 ± 0.3 and the transplanted pTLCratio after lobar resection was 0.76 ± 0.2. One-year survival in the ddLLTx-group ranged from 50%-100%, compared to 72%-88% in the conventional-LTx group. In the largest study ddLLTx (n = 138) was associated with a lower one-year-survival compared to conventional-LTx (n = 539) (65.1% vs 84.1%, P < 0.001). Further investigations of optimal donor-to-recipient size matching parameters for ddLLTx could improve outcomes of this important surgical option.